Grants / Department of Defense / Defense Health Agency Contracting Activity - DHACA

W81XWH-21-ERP-RPA: DoD Epilepsy, Research Partnership Award

Closed Closed July 21, 2021 Opportunity W81XWH-21-ERP-RPA ☆ Save

This grant is closed. A newer notice from the same program is open now: DoW Breast Cancer, Clinical Research Extension Award (HT942526BCRPCREA2). Status: Closes November 18, 2026 (11 days left). It is in our archive of Defense Health Agency Contracting Activity - DHACA notices from 2021.

• Total funding$4.4 million
• Expected awards2
• Cost sharingNot required
• Funding typeCooperative Agreement, Grant

Key dates

Who can apply

This opportunity was open to any type of organization.

• Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

More grants for nonprofits, colleges and universities, state and local governments, tribes, small businesses, businesses, individuals.

Is this a realistic fit?

• Most of the program's money (59% over five years) went to colleges and universities.
• No cost sharing or match is required.

What the grant funds

The intent of the FY21 ERP RPA is to create an avenue for collaborative research partnerships between/among investigators to address a research problem or question in a manner that would be unachievable through separate efforts. Applications must describe how the anticipated outcome(s) can be attributable to the results of the proposed research (short-term gains), as well as consider the long-term scientific gains from the proposed research project. The research impact for the FY21 ERP RPA is expected to benefit the military, Veteran, and civilian communities. Applications must be impact-based. FY21 ERP RPA Focus Areas: The Focus Areas below are specific to the FY21 ERP RPA. Applicants to the FY21 ERP RPA must select from the relevant Funding Level I or Funding Level II Focus Areas.  Markers and Mechanisms (Funding Level I Only): Identifying markers or mechanisms via preclinical models that address PTE, which may include the following: ○ Biomarkers (acute and chronic) ○ Treatment ○ Prevention ○ Comorbidity  Epidemiology (Funding Level I Only): Epidemiological characterization of PTE following TBI, which may include the following: ○ Risk factors such as demographics, genetics, anatomy, pathology, or type of injury ○ Outcomes including latency to epilepsy, comorbidities, and mortality ○ Pre-existing conditions including psychological and psychiatric risk factors ○ Treatment and healthcare outcomes research ○ Differentiation of PTE and psychogenic non-epileptic seizures (PNES)  Longitudinal Studies (Funding Level II Only): Studies of the evolution of PTE, which may include the following: ○ Seizure frequency and semiology ○ Demographics, genetics, anatomy, pathology, or type of injury ○ Comorbidities (e.g., depression, functional deficits, sleep disorders, major illness) ○ Latency between type of injury and PTE ○ Mortality ○ Treatment and healthcare outcomes research The FY21 ERP RPA offers two levels of funding. The application requirements for each funding level are detailed below. For Funding Level I: Funding Level I is intended to support preclinical or pre-validation research. For Funding Level II: Funding Level II requires access to a patient cohort for a prospective study and must be the focus of the application. Funding Level II applications that evaluate the feasibility of using combinations of measures (e.g., neuropsychological assessments, imaging, and genomics) are encouraged.

Category: Science and Technology and other Research and Development.

Applying now

This notice no longer takes applications. Apply under the newer notice, HT942526BCRPCREA2, which is open now.

The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.